

Curriculum Vitae

Personal information **Serena Marchetti**

Work experience

1. Employer: Pistoia Hospital
 - Start date: 2003
 - End date: 2004
 - Position: Staff Member Department of Emergency Medicine
 - Activities: Activity in in_ and out_of_hospital Emergency Medicine Department.
 - Country: Italy
2. Employer: Campo di Marte Hospital, Lucca
 - Start date: 2006
 - End date: 2007
 - Position: Staff Member Department of Internal Medicine, section of Medical Oncology
 - Activities: Daily care of in_ and out_of_hospital patients with common oncological diseases. Interdivisional night and week_end activity of in_hospital patients attended to the Departments of Internal Medicine, Gastroenterology, or Medical Oncology.
 - Country: Italy
3. Employer: The Netherlands Cancer Institute; The Dutch Medicines Evaluation Board
 - Start date: 2007
 - End date:
 - Position: Medical Oncologist, Clinical Assessor for Oncological products
 - Activities: Daily care of in_ and out_of_hospital patients with common oncological diseases. Clinical assessment for the Dutch Medicines Evaluation Board regarding registration of new drugs in the field of oncology and hematology.
 - Country: Netherlands

Education and training

1. Subject: State University Florence
 - Start date: 1993
 - End date: 1999
 - Qualification: Medical Doctor
 - Organisation: Education and training in medicine and surgery. Awarded qualification as Medical Doctor (cum laude)
 - Country: Italy
2. Subject: State University Florence
 - Start date: 1999
 - End date: 2003
 - Qualification: Board certified Medical Oncologist
 - Organisation: Daily training on clinical care of patients with internal medicine diseases and training on clinical care of in_ and out_of_hospital patients with common oncological diseases. Board certified Medical Oncologist (cum laude)
 - Country: Italy
3. Subject: Campo di Marte Hospital, Pistoia
 - Start date: 2002
 - End date: 2002
 - Qualification: Diploma for Emergency medicine activity
 - Organisation: Training in in_ and out_of_hospital medical emergencies, training course with diplomas in Basic Life Support (BLS), Basic Life Support – Defibrillation, Pediatric Basic Life Support (PBLs), Advanced Life Support (ALS), Advanced Traumatic Life Support (ATLS), according to the International Resuscitation Council (IRC)
 - Country: Italy
4. Subject: State University Florence
 - Start date: 2003
 - End date: 2007
 - Qualification: PhD
 - Organisation:
 - Country: Italy
5. Subject: University of Utrecht
 - Start date: 2013
 - End date: 2013
 - Qualification: PhD
 - Organisation:
 - Country: Netherlands
6. Subject:
 - Start date: 2015
 - End date:
 - Qualification: GCP Certificate
 - Organisation:
 - Country: Netherlands
7. Subject:
 - Start date: 2019
 - End date:
 - Qualification: GCP certificate renewal

- Organisation:
- Country: Netherlands

Additional information

Publications

Mazzanti R, Arena U, Pantaleo P, Antonuzzo L, Cipriani G, Neri B, Giordano C, Lanini F, Marchetti S, Gentilini P. Survival and prognostic factors in patients with hepatocellular carcinoma treated by percutaneous ethanol injection: a 10_year experience. *Can J Gastroenterol*. 2004 Oct;18(10):611-8. Lasagna N, Fantappiè O, Solazzo M, Morbidelli L, Marchetti S, Cipriani G, Ziche M, Mazzanti R. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance_induced angiogenesis in hepatocellular carcinoma cell lines. *Cancer Res*. 2006; 66: 2673-82. Oostendorp RL, Marchetti S, Beijnen JH, Mazzanti R, Schellens JHM. The effect of hydroxyurea on P_glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate. *Cancer Chemother Pharmacol*. 2007; 59: 855-60. Marchetti S, Schellens JHM. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. *Br J Cancer*. 2007; 97: 577-81. Marchetti S, Mazzanti R, Beijnen JH, Schellens JHM. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P_glycoprotein). *Oncologist*. 2007; 12: 927-41. Marchetti S, Oostendorp RL, Pluim D, van Eijndhoven M, van Tellingen O, Schinkel AH, Versace R, Beijnen JH, Mazzanti R, Schellens JHM. In vitro transport of gimatecan (7_t_butoxyiminomethylcamptothecin) by breast cancer resistance protein, P_glycoprotein, and multidrug resistance protein 2. *Mol Cancer Ther*. 2007; 6: 3307-13. Marchetti S, Mazzanti R, Beijnen JH, Schellens JHM. Clinical relevance: drug_drug interaction, pharmacokinetics, pharmacodynamics, and toxicity. *Drug Transporters, Molecular Characterization and role in Drug Disposition*. John Wiley & Sons. 2007; 24: 747-880. Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JHM. Effect of the ATP_binding cassette drug transporters ABCB1, ABCG2, and ABCG2 on erlotinib hydrochloride (Tarceva) disposition in vitro and in vivo pharmacokinetic studies employing Bcrp1_/_/Mdr1a/1b_/_/ (triple_knockout) and wild_type mice. *Mol Cancer Ther*. 2008; 7: 2280-7. Devriese LA, Witteveen PO, Marchetti S, Mergui_Roelvink M, Reyderman L, Wanders J, Jenner A, Edwards G, Beijnen JH, Voest EE, Schellens JHM. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. *Cancer Chemother Pharmacol*. 2012; 70: 823-32. Dubbelman AC, Uthagrove A, Beijnen JH, Marchetti S, Tan E, Krone K, Anand S, Schellens JHM. Disposition and metabolism of 14C_dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2012; 70: 653-63. Devriese LA, Mergui_Roelvink M, Wanders J, Jenner A, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Schellens JHM. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. *Invest New Drugs*. 2013; 31: 381-9. Devriese LA, Witteveen PE, Wanders J, Law K, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Huitema AD, Voest EE, Schellens JHM. Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. *Br J Clin Pharmacol*. 2013; 75: 507-15. da Rocha Dias S, Salmonson T, van Zwielen Boot B, Jonsson B, Marchetti S, Schellens JHM, Giuliani R, Pignatti F. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation_positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. *Eur J Cancer*. 2013; 49: 1654-61. Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JHM, Beijnen JH, van Tellingen O. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. *Clin Cancer Res*. 2013; 19: 2084-95. Marchetti S, Pluim D, van Eijndhoven M, van Tellingen O, Mazzanti R, Beijnen JH, Schellens JHM. Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCG2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib_hydroxy_QPA. *Invest New Drugs*. 2013; 31: 1125-35. Marchetti S, Schellens JHM. Clinical relevance: drug_drug interaction, pharmacokinetics, pharmacodynamics, and toxicity. Update. In *Drug Transporters, Molecular Characterization and role in Drug Disposition*. John Wiley & Sons. 2013. Moes JJ, Stuurman FE, Hendriks JJ, Marchetti S, Huitema AD, Beijnen JH, Schellens JH, Nuijen B. Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single_drug formulations vs. a fixed_dose combination tablet. *Drug Deliv Transl Res*. 2013 Jun;3(3):243-51. Goey AK, Meijerman I, Rosing H, Burgers JA, Mergui_Roelvink M, Keessen M, Marchetti S, Beijnen JH, Schellens JH. The effect of Echinacea purpurea on the pharmacokinetics of docetaxel. *Br J Clin Pharmacol*. 2013 Sep;76(3):467-74. Marchetti S, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. Effect of the drug transporters ABCB1, ABCG2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS_275,183". *Invest New Drugs*. 2014 Dec;32(6):1083-95. Jacobs BA, Meulenaar J, Rosing H, Pluim D, Tibben MM, de Vries N, Nuijen B, Huitema AD, Beijnen JH, Schellens JH, Marchetti S. A phase 0 clinical trial of novel candidate extended_release formulations of capecitabine. *Cancer Chemother Pharmacol*. 2016 Jun;77(6):1201-7. Nijenhuis CM, Huitema AD, Marchetti S, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH. The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients. *J Clin Pharmacol*. 2016 Oct;56(10):1307-12. de Weger VA, Stuurman FE, Koolen SLW, Moes JJ, Hendriks JJMA, Sawicki E, Thijssen B, Keessen M, Rosing H, Mergui_Roelvink M, Huitema AD, Nuijen B, Beijnen JH, Schellens JHM, Marchetti S. A Phase I Dose Escalation Study of Once_Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir. *Clin Cancer Res*. 2019 Sep 15;25(18):5466-5474. de Weger VA, Stuurman FE, Hendriks JJMA, Moes JJ, Sawicki E, Huitema AD, Nuijen B, Thijssen B, Rosing H, Keessen M, Mergui_Roelvink M, Beijnen JH, Schellens JHM, Marchetti S. A dose_escalation study of bi_daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir. *Eur J Cancer*. 2017 Nov;86:217-225. Yu H, Janssen JM, de Weger VA, Nuijen B, Stuurman RE, Marchetti S, Schellens JHM, Beijnen JH, Dorlo TPC & Huitema AD. Quantification of the pharmacokinetic_toxicodynamic relationship of oral docetaxel co_administered with ritonavir. *Investigational New Drugs volume 38, pages 1526-1532 (2020)* Hendriks JJMA, Stuurman FE, Song JY, de Weger VA, Lagas JS, Rosing H, Beijnen JH, Schinkel AH, Schellens JHM, Marchetti S. No relation between docetaxel administration route and high_grade diarrhea incidence. *Pharmacol Res Perspect*. 2020 Aug;8(4):e00633. Roosendaal J, Jacobs BAW, Pluim D, Rosing H, de Vries N, van Werkhoven E, Nuijen B, Beijnen JH, Huitema AD, Schellens JHM, Marchetti S. Phase I pharmacological study of continuous chronomodulated capecitabine treatment. *Pharm Res*. 2020 May 7;37(5):89. Duinkerken CW, de Weger VA, Dreschler WA, van der Molen L, Pluim D, Rosing H, Nuijen B, Hauptmann M, Beijnen JH, Balm AJM, de Boer JP, Burgers JA, Marchetti S, Schellens JHM, Zuur CL. Transtympanic Sodium Thiosulfate for Prevention of Cisplatin_Induced Ototoxicity: A Randomized Clinical Trial. *Otol Neurotol*. 2021 Jun 1;42(5):678-685. Vermunt M, Marchetti S, Beijnen J. Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co_Administered with Ritonavir in Phase I Trials. *Clin Pharmacol*. 2021 Jan 27;13:21-32. Vermunt MAC, de Weger VA, Janssen JM, Lopez_Yurda MI, Keessen M, Thijssen B, Rosing H, Huitema AD, Beijnen JH, Marchetti S. Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours. *Drugs R D*. 2021 Mar;21(1):103-111. Janssen JM, Jacobs BAW, Roosendaal J, Derissen EJB, Marchetti S, Beijnen JH, Huitema AD, Dorlo TPC. Population Pharmacokinetics of Intracellular 5'_Fluorouridine 5'_Triphosphate and its Relationship with Hand_and_Foot Syndrome in Patients Treated with Capecitabine. *AAPS J*. 2021 Jan 8;23(1):23. van Eijk M, Pluim D, Dorlo TPC, Marchetti S, Huitema AD, Beijnen JH. Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir. *Pharmacogenomics J*. 2021 Jun;21(3):336-345.

Projects

Memberships

Other Relevant Information

Since August 2022 I am member of the ethical committee at the Netherlands Cancer Institute